Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Santa Fe, NM
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
New York, NY
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Greensboro, NC
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Cleveland, OH
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Franklin, OH
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Franklin, OH
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
East Providence, RI
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
East Providence, RI
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Greer, SC
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Simpsonville, SC
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Simpsonville, SC
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Cite, TN
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Cite, TN
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Kingsport, TN
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Dallas, TX
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
San Antonio, TX
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Tyler, TX
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
West Jordan, UT
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Virginia Beach, VA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Edmonds, WA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Edmonds, WA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Everett, WA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Monroe, WA
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Monroe, WA
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Wauwatosa, WI
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Capital Federal,
Study In People With Type 2 Diabetes
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Capital Federal,
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
New England Diabetes and Endocrinology Center (NEDEC)
mi
from
Waltham, MA
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
New England Diabetes and Endocrinology Center (NEDEC)
mi
from
Waltham, MA
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Albany Medical College Division of Community Endocrinology
mi
from
Albany, NY
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Albany Medical College Division of Community Endocrinology
mi
from
Albany, NY
Click here to add this to my saved trials
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  3/22/2017
Winnipeg Clinic
mi
from
Winnipeg,
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 3/22/2017
Winnipeg Clinic
mi
from
Winnipeg,
Click here to add this to my saved trials
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects
Status: Enrolling
Updated:  3/22/2017
Novo Nordisk Investigational Site
mi
from
Evansville, IN
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
Investigation on Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects. A Randomised, Double-blind, Placebo-controlled Trial Investigating Subcutaneously Single Dose Escalation of a Sustained Release Formulation of Liraglutide Lysine in Healthy Male Subjects
Status: Enrolling
Updated: 3/22/2017
Novo Nordisk Investigational Site
mi
from
Evansville, IN
Click here to add this to my saved trials
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide
Status: Enrolling
Updated:  3/23/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
The Effects of Open Label Alpha-1 Antitrypsin on the Progression of Type 1 Diabetes in Subjects With Detectable C-peptide
Status: Enrolling
Updated: 3/23/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Stanford University
mi
from
Stanford, CA
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Aurora, CO
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Yale University
mi
from
New Haven, CT
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
University of Florida
mi
from
Gainesville, FL
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
University of Miami
mi
from
Miami, FL
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Indiana University-Riley Hospital for Children
mi
from
Indianapolis, IN
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Indiana University-Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Columbia University
mi
from
New York, NY
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Vanderbilt Eskind Diabetes Clinic
mi
from
Nashville, TN
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Vanderbilt Eskind Diabetes Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
University of Texas
mi
from
Dallas, TX
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
University of Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Benaroya Research Institute
mi
from
Seattle, WA
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Benaroya Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  3/27/2017
Walter and Eliza Hall Institute
mi
from
Parkville,
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 3/27/2017
Walter and Eliza Hall Institute
mi
from
Parkville,
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Catalina Research Institute
mi
from
Chino, CA
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Catalina Research Institute
mi
from
Chino, CA
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Palm Beach Research
mi
from
Palm Beach, FL
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Palm Beach Research
mi
from
Palm Beach, FL
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Meridien Research
mi
from
Tampa, FL
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Meridian Research
mi
from
Savannah, GA
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Meridian Research
mi
from
Savannah, GA
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Streling Research Group
mi
from
Cincinnati, OH
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Streling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Medical Research South
mi
from
Charleston, SC
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Medical Research South
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  3/27/2017
Meharry Medical College
mi
from
Nashville, TN
Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 3/27/2017
Meharry Medical College
mi
from
Nashville, TN
Click here to add this to my saved trials